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Introduction
Insul in therapy is a standard treatment for diabetes, essential in patients with type 1 diabetes mellitus (T1DM) and frequently necessary in patients with type 2 diabetes mellitus (T2DM) as the condition of their disease progresses. 1 Despite the confirmed benefits of insulin therapy for patients with T2DM, [2] [3] [4] [5] [6] [7] [8] [9] [10] there is a resistance on the part of both patients and physicians to begin insulin therapy for the treatment of T2DM. 11 This resistance has been termed "psychological insulin resistance," which is a general term encompassing many psychological factors, such as needle anxiety, social embarrassment, and fears of the risks of weight gain and hypoglycemia. 11 Even though the consequences can be negative, psychological insulin resistance appears also to affect adherence with insulin treatment plans. One study estimated that only 63% of patients with T2DM took their insulin doses as prescribed. 12 The Diabetes Attitudes, Wishes, and Needs (or DAWN) study has indicated that the way to overcome the patient's and physician's psychological barriers to initiating insulin therapy is through innovative management techniques and improving insulin delivery systems. 11 Compared with conventional vial and syringe delivery, pen devices have simplified the administration of insulin, and patients express a preference for using them. [13] [14] [15] [16] [17] Users have reported an improved quality of life, greater ability to adhere to treatment regimens, and more accurate dosing when self-injecting insulin with a pen instead of a syringe. 18, 19 The durable insulin pen NovoPen ® 4 (Novo Nordisk A/S, Bagsvaerd, Denmark) was designed to enhance the ease with which health care professionals instruct patients in its use and the ability of patients to handle it, compared with NovoPen 3. Both pens have been shown to deliver accurate doses of insulin over a period of 5 years under simulated testing conditions in which pens were also exposed to mechanical and temperature stresses that could occur in daily patient use. 20, 21 The changes in NovoPen 4 compared with NovoPen 3 include ability for the selector dial to be turned backward and forward without wasting insulin when adjusting dosage; automatic zero positioning of the dosage scale after injection; inability to select more insulin than what remains in the cartridge; audible end-of-dose click; easy to push back piston rod; bayonet interface for the two parts of the pen that require only a quarter turn, simplifying cartridge replacement; easier-to-read dosage scale with numbers more than four times larger (p < .001); 22 reduced injection force of approximately 50% throughout the specified lifetime of the pen; 22 and, lastly, a noticeably smaller pen size.
The aim of this trial was to investigate which insulin pen, NovoPen 4 or NovoPen 3, was preferred by patients with T1DM or T2DM by comparing how much time was required to train participants in the use of either pen and how the participants assessed intuitiveness, performance, acceptance, and handling of the pens. A secondary goal was to determine any adverse device effects.
Methods

Ethics Statement
The study was conducted in accordance with the Declaration of Helsinki and approved by the ethics committees of the Prevention Center University Hospital in Salzburg and Servizio di Diabetologia Azienda USL in Reggio Emilia. All patients gave written consent before being enrolled in the study. They also gave verbal informed consent prior to each testing step.
Patients
A total of 117 patients with T1DM or T2DM were enrolled in this open-label, crossover handling test in two countries. They were recruited to study centers in either Austria or Italy. All patients were adults at least 18 years old, and they currently used NovoPen 3 (n = 82) or vial and syringe (n = 1) or were insulin naïve (n = 34). No NovoPen 3 user had previous experience with NovoPen 4. Fifty-one of the patients had T1DM and 65 had T2DM. Complete demographic information about the patients, with the exception of the sole vial and syringe user whose responses were not included in the study results, appears in Table 1 .
Potential participants were excluded if they were suspected of abusing alcohol or drugs; were judged to have significant visual impairment, which was considered as having difficulty in reading and performing daily tasks due to lack of vision; were judged to have significant dexterity impairment, which was considered as difficulty in performing daily tasks due to motor dysfunction caused by conditions such as neuropathy, arthritis, familiar tremor, Parkinson's disease, stroke-induced partial paralysis, or generalized lupus; were suffering from a serious chronic disease that made completion of the study unlikely; or had a mental incapacity, unwillingness, or language barrier that prevented adequate mutual understanding or cooperation.
Study Design
In the first part of the study, all participants currently using NovoPen 3 (n = 82) were given a NovoPen 4 intuitiveness assessment with a maximum 5 min time limit by a diabetes nurse educator (DNE). Participants were handed a NovoPen 4 device containing an empty Penfill ® (Novo Nordisk A/S) cartridge with no needle attached and then asked to replace the cartridge, attach a NovoFine ® (Novo Nordisk A/S) 31 G needle, select 20 U, and deliver the selected dose into a foam cushion. The DNE recorded the amount of time needed if the patient successfully completed the sequence of tasks within 5 min. The patient's attempt was recorded as unsuccessful if the allotted time passed before completion of the tasks.
For the second part of the study, the two groups of patients-NovoPen 3 users and insulin-naïve patientswere each divided in half. One half of each group first evaluated NovoPen 3 then NovoPen 4, while the other half evaluated the pens in the reverse order (Figure 1 ). Patients were instructed in the use of each pen before completing a series of tasks unassisted. Current NovoPen 3 users, however, who were to test NovoPen 3 did not receive instruction on use of this pen. The amount of time required for training patients was recorded. To successfully perform the tasks, the patient had to insert a Penfill cartridge into the pen; attach a NovoFine 31 G needle; prime the pen; deliver three doses of 6, 25, and 60 U into a foam cushion; and correct a dosage amount from 30 to 25 U. The DNE recorded whether the patient completed the tasks successfully without assistance and if there were any adverse device effects. The patient then completed a questionnaire about that specific device before repeating the process with the other pen. After assessing that device, the patient completed a questionnaire comparing both devices.
The device-specific questionnaires were identical, except that the one for evaluating NovoPen 4 had three additional questions about the unique features of NovoPen 4 relating to its inability to have a dosage set higher than the amount remaining in the cartridge and the audible endof-dose click. The 20 questions that the questionnaires had in common asked patients to rate various aspects of using the pens on a five-point scale, including how easy it was to set the required dose, press the injection button, change the Penfill cartridge, and learn how to use the device. Patients were also asked to assess the pens' appearance. Table 2 contains all questions asked on the two device-specific questionnaires. In the comparative questionnaire at the end of the study, patients were asked to identify which pen was easiest to operate for a variety of handling characteristics and which pen they would prefer to use. Three answer choices were possible Test products (both pen devices and insulin cartridges) were provided by Novo Nordisk A/S, Hillerød, Denmark. Adverse device effects monitored during the study included any deficiencies related to the identity, quality, durability, reliability, safety, or performance of either NovoPen 4 or NovoPen 3 that resulted in, or could have resulted in, a serious injury.
Statistical Methods
The primary end point of the trial-preference for using either NovoPen 4 or NovoPen 3-was evaluated by a superiority test, where superiority was claimed if the lower limit of the two-sided 95% confidence interval for the difference in preference between NovoPen 4 and NovoPen 3 was above 0%. 
Results
Intuitive Assessment
All 82 current NovoPen 3 users were able to complete the intuitive test for using NovoPen 4 within the 5 min time limit. The average amount of time needed to complete the sequence of tasks that demonstrated the ability to load the newer pen with a cartridge and discharge a 20 U dose into a foam cushion was 1.94 min (range, 0.57-4.98 min).
Training Time and Device-Specific Responses
The average amount of time needed to instruct patients in the insulin-naïve group so that they could successfully complete the series of handling tasks with NovoPen 3 was 11.5 min (range, 4.1-31.8 min). On average, patients required 9.9 min (range, 3.5-22.3 min) to learn how to use NovoPen 4, but the difference in learning times was insignificant (p = .32). Current NovoPen 3 users needed an average of 4.9 min (range 2.2-12.6 min) of instruction time before starting the handling tasks with NovoPen 4.
The results of the device-specific questionnaires suggest that, in general, patients in the insulin-naïve group had more difficulty and were less confident in operating both pens than the group of NovoPen 3 users ( Table 2) . For every question from 1 to 20 on both questionnaires, a greater percentage of the NovoPen 3 users responded "very easy," "very confident," and "very appropriate/ suitable" than patients in the insulin-naïve group.
Both groups claimed to have less difficulty and were more confident handling NovoPen 4 than NovoPen 3. When asked how easy it was to set the required dose for NovoPen 3, 79.3% of NovoPen 3 users and 41.1% of insulin-naïve patients responded "very easy" or "easy." However, 100% of both groups described setting the dose for NovoPen 4 as "very easy" or "easy." One hundred percent of both groups also considered it "very easy" or "easy" to push down the injection button on NovoPen 4 and thought that, overall, the ease of using this pen was "very convenient" or "pretty convenient." In comparison, 73.1% of NovoPen 3 users and 44.1% of insulin-naïve patients answered that it was "very easy" or "easy" to push down the NovoPen 3 injection button, and 81.7% and 85.3% of each group felt it was "very convenient"
or "pretty convenient" to use NovoPen 3. NovoPen 4 was rated easier to learn how to use: 100% of current NovoPen 3 users and 82.4% of the other group claimed it as "very easy" or "easy" to learn, while only 75.6% and 32.3% of the respective groups gave NovoPen 3 such high marks. More than 85% of the subjects in both groups also found the appearance of NovoPen 4 to be "pretty appropriate" or "very appropriate." NovoPen 4 was viewed as having a "very appropriate" appearance by 72.0% and 67.6% by the current NovoPen 3 users and insulin-naïve group, respectively. The corresponding percentages for NovoPen 3 were 29.3% and 17.6%, respectively.
Comparative Responses
When asked to directly compare the two pens, both groups expressed a clear preference for NovoPen 4 (Figure 2) . The preference in response to all questions was highly significant (p < .0001). One hundred percent of insulinnaïve patients and 96.3% of current NovoPen 3 users expressed a preference for NovoPen 4. No participant in this group preferred NovoPen 3 for any of the eight evaluative criteria, although for five criteria, a few participants thought there was no difference between the pens. When asked which device they would recommend to others, 97.6% of current NovoPen 3 users and 97.1% of insulin-naïve patients replied NovoPen 4; 96.3% and 100% of the groups, respectively, said they would prefer to use NovoPen 4.
No adverse effects for either pen were recorded during the handling tests. As only one vial and syringe user was enrolled in the study, responses from this patient were not included in the results.
Discussion
In this handling trial and patient preference evaluation of NovoPen 4 versus NovoPen 3, both current NovoPen 3 users and insulin-naïve patients ranked NovoPen 4 as easier to use and more suitable against a variety of handling criteria. Although the insulin-naïve group did not rate either pen as high as the current NovoPen 3 users did in their responses to the device-specific questions, this difference should be expected, because the insulin-naïve patients had no prior experience with insulin therapy and were less confident operating the pens than the other group. NovoPen 3 users quickly determined without assistance how to use the newer pen, completing the intuitive assessment test in an average of 1.94 min. It took less time for the insulin-naïve patients to be instructed in the sequence of handling tasks for NovoPen 4, compared with the amount of time for Although the experience of NovoPen 3 users with this pen device was not controlled for in the analysis of results, our study's main end point showing a preference for NovoPen 4 does not appear to be affected. In fact, the previous use of NovoPen 3 by these users probably explains why there were more "no difference" responses from this group than from insulin-naïve users in the answers to the comparative questionnaire. All insulinnaïve patients considered it easier to set the dose for and read the dosage scale of the NovoPen 4, but in the NovoPen 3 group, 17 and 6 people (20.7% and 7.3%), respectively, replied that there was no difference between the two pens (Figure 2 , responses to questions 1 and 2). Most likely, the previous experience of NovoPen 3 users influenced their answers.
The results of our study are consistent with the findings of a randomized 12-week study in which 208 patients with diabetes who had been on insulin therapy for more than 1 year compared daily usage of NovoPen 4 with NovoPen 3. 23 After using each pen for 6 weeks, 81% expressed an overall preference for NovoPen 4 (p < .05), 9% for NovoPen 3, and 10% had no preference. In another study evaluating patient preference for NovoPen 4 versus OptiClik ® (sanofi-aventis, Bridgewater, NJ), after completing a randomized handling test with both pens, 32 of 35 patients with diabetes (91.4%; p < .001) responded on the questionnaire that they would prefer to use NovoPen 4. 24 Patients in this study also rated NovoPen 4 as more intuitive to use (83.3% versus 5.6%; p < .001) and identified NovoPen 4 as "very easy" or "easy" to learn more often than OptiClik (80% versus 22.9%; p < .001). 24 The preference shown for NovoPen 4 in these studies, including ours, cannot be explained by the presence of any one feature. NovoPen 4 has a number of design enhancements compared with previous versions of NovoPen, including a dosage scale selector that turns forward and backward, a more visible dosage scale, an audible end-of-dose click, and less injection force required to deliver insulin, which all have been seen to improve ease of use and increase preference. 22, 24 Other factors that can influence patient satisfaction are the level of individualized, verbal instruction that they receive and the provision of written material. 25, 26 In this study, after the initial intuitive assessment of NovoPen 4, patients received detailed, personalized demonstrations and explanations for using this device until they could confidently handle it. In a normal clinical setting, patients do not always receive such patient-centered communication, although it has been shown to increase patient satisfaction. 27 Even if intensive patient-centered communication is delivered, however, patients should also receive both medical information about their treatment, which has been shown to increase patient knowledge and consequently treatment satisfaction, 26 and an operating manual for the specific pen device they will use that is easy to read and follow, which can be referred to, for instance, when patients need to change an insulin cartridge or a technical device problem arises.
As the number of people diagnosed with T1DM and T2DM continues to grow worldwide, 28 insulin delivery devices that are easy to learn and easy to teach can help overcome the psychological insulin resistance patients and physicians have to initiating insulin therapy and encourage patients to establish better metabolic control over their disease. 11 In our study, insulin-naïve participants learned more quickly how to complete the handling tasks with NovoPen 4 than with NovoPen 3. All NovoPen 3 users were able to grasp intuitively how the newer NovoPen worked. Ease of learning, along with the high ratings NovoPen 4 received from both groups for ease of use, convenience, and appearance suggest that this pen would be suitable for patients who are currently on insulin therapy, as well as for those in whom insulin should be initiated.
Conclusions
The durable insulin device NovoPen 4 is simpler to learn, easier to use, and more appropriate in appearance than NovoPen 3. In our study, 96.3% of NovoPen 3 users and 100% of insulin-naïve patients selected for inclusion declared that they preferred to use NovoPen 4 rather than the previous version of NovoPen (p < .0001). The mean times required to complete handling tasks and educate participants, along with the responses to questionnaires, suggest that, overall, both the current NovoPen 3 users and insulin-naïve patients had less difficulty and were more confident handling NovoPen 4 than NovoPen 3.
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